Transformative, a NYC-based healthcare startup whose software predicts sudden cardiac arrest, raised $1.7m in seed funding.
The round was led by Tera Ventures, with participation from the Wellcome Trust and InHealth Ventures. In conjunction with the funding, Andrus Oks of Tera Ventures and Nick Slater of AI Seed are joining Transformative’s board.
The company will use the funds to obtain FDA clearance for its first product and to begin developing technologies that predict other life-threatening conditions.
Co-founded by CEO Josh Oppenheimer, MD, MBA, Marek Sirendi, PhD, and Marek Rei, PhD, Transformative provides patented technology that predicts sudden cardiac arrest by analyzing data from patient monitoring devices that are standard in hospitals, enabling preventive care. The company, which operates in the US, the UK, and Estonia, was formed in 2016 through Entrepreneur First’s startup program and participated in the Philips HealthWorks program.